Avanos Medical (AVNS) Stock Forecast, Price Target & Predictions
AVNS Stock Forecast
Avanos Medical stock forecast is as follows: an average price target of $27.00 (represents a 12.50% upside from AVNS’s last price of $24.00) and a rating consensus of 'Hold', based on 2 wall street analysts offering a 1-year stock forecast.
AVNS Price Target
The average price target for Avanos Medical (AVNS) is $27.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $26.00. This represents a potential 12.50% upside from AVNS's last price of $24.00.
AVNS Analyst Ratings
According to 2 Wall Street analysts, Avanos Medical's rating consensus is 'Hold'. The analyst rating breakdown for AVNS stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (50.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).
Avanos Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 06, 2023 | - | Morgan Stanley | $26.00 | $26.99 | -3.67% | 8.33% |
| Jul 18, 2022 | - | Stifel Nicolaus | $28.00 | $26.89 | 4.13% | 16.67% |
| Jul 15, 2022 | - | Morgan Stanley | $28.00 | $27.19 | 2.98% | 16.67% |
| May 05, 2022 | - | Morgan Stanley | $33.00 | $29.29 | 12.67% | 37.50% |
The latest Avanos Medical stock forecast, released on Jan 06, 2023 by Morgan Stanley company, set a price target of $26.00, which represents a -3.67% decrease from the stock price at the time of the forecast ($26.99), and a 8.33% increase from AVNS last price ($24.00).
Avanos Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $24.00 | $24.00 | $24.00 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Avanos Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Avanos Medical's last price of $24.00. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 06, 2023 | Morgan Stanley | Underweight | Underweight | Hold |
| Jul 15, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Downgrade |
Avanos Medical's last stock rating was published by Morgan Stanley on Jan 06, 2023. The company gave AVNS a "Underweight" rating, the same as its previous rate.
Avanos Medical Financial Forecast
Avanos Medical Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $171.30M | $169.40M | $191.70M | $217.50M | $202.10M | - | $197.40M | $193.40M | $184.10M | $186.40M | $180.70M | $185.00M | $185.70M | $163.70M | $180.40M | $189.80M | $171.40M | $172.20M | $164.20M | $169.90M | $165.10M |
| Avg Forecast | $191.33M | $184.30M | $180.07M | $174.10M | $182.30M | $175.20M | $170.67M | $162.90M | $170.43M | $169.60M | $186.30M | $195.20M | $217.30M | $205.47M | $208.28M | $197.80M | $191.32M | $185.02M | $180.56M | $175.68M | $184.15M | $165.87M | $147.90M | $175.77M | $178.58M | $179.98M | $172.02M | $163.72M | $118.42M | $116.02M |
| High Forecast | $191.52M | $184.48M | $180.24M | $174.27M | $182.48M | $175.57M | $170.83M | $163.06M | $174.84M | $170.00M | $186.48M | $195.39M | $217.51M | $205.67M | $208.28M | $200.18M | $193.63M | $187.25M | $182.73M | $177.79M | $186.36M | $167.86M | $149.68M | $177.88M | $180.73M | $182.15M | $174.09M | $165.69M | $142.10M | $139.22M |
| Low Forecast | $191.08M | $184.06M | $179.83M | $173.87M | $182.06M | $174.77M | $170.44M | $162.69M | $167.59M | $168.80M | $186.06M | $194.94M | $217.01M | $205.20M | $208.28M | $195.67M | $189.27M | $183.03M | $178.62M | $173.79M | $182.17M | $164.08M | $146.31M | $173.88M | $176.66M | $178.05M | $170.17M | $161.96M | $94.73M | $92.81M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 0.91% | 0.98% | 1.00% | 0.98% | - | 1.00% | 1.01% | 1.00% | 1.03% | 1.03% | 1.00% | 1.12% | 1.11% | 1.03% | 1.06% | 0.95% | 1.00% | 1.00% | 1.43% | 1.42% |
Avanos Medical's average Quarter revenue forecast for Dec 23 based on 3 analysts is $170.43M, with a low forecast of $167.59M, and a high forecast of $174.84M. AVNS's average Quarter revenue forecast represents a -0.51% decrease compared to the company's last Quarter revenue of $171.30M (Sep 23).
Avanos Medical EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | - | $13.10M | $9.90M | $15.20M | $40.30M | $30.60M | - | $20.30M | $34.50M | $13.40M | $2.20M | $-2.70M | $-33.90M | $10.80M | $9.20M | $11.90M | $9.10M | $-8.10M | $700.00K | $-13.80M | $3.60M | $18.10M |
| Avg Forecast | $13.00M | $12.52M | $12.23M | $11.83M | $12.39M | $11.90M | $11.59M | $24.56M | $11.58M | $11.52M | $12.66M | $22.33M | $14.76M | $15.83M | $14.15M | $20.30M | $29.32M | $14.39M | $2.39M | $-2.13M | $-24.65M | $8.67M | $27.32M | $11.90M | $8.53M | $-8.36M | $700.00K | $-11.68M | $2.24M | $11.49M |
| High Forecast | $13.01M | $12.53M | $12.25M | $11.84M | $12.40M | $11.93M | $11.61M | $29.48M | $11.88M | $11.55M | $12.67M | $26.80M | $14.78M | $19.00M | $14.15M | $24.36M | $35.19M | $17.27M | $2.87M | $-1.71M | $-19.72M | $10.40M | $32.79M | $14.28M | $10.24M | $-6.69M | $840.00K | $-9.34M | $2.69M | $13.78M |
| Low Forecast | $12.98M | $12.50M | $12.22M | $11.81M | $12.37M | $11.87M | $11.58M | $19.65M | $11.39M | $11.47M | $12.64M | $17.86M | $14.74M | $12.67M | $14.15M | $16.24M | $23.46M | $11.51M | $1.91M | $-2.56M | $-29.59M | $6.94M | $21.86M | $9.52M | $6.83M | $-10.03M | $560.00K | $-14.01M | $1.79M | $9.19M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.14% | 0.78% | 0.68% | 2.73% | 1.93% | - | 1.00% | 1.18% | 0.93% | 0.92% | 1.27% | 1.38% | 1.25% | 0.34% | 1.00% | 1.07% | 0.97% | 1.00% | 1.18% | 1.61% | 1.58% |
3 analysts predict AVNS's average Quarter EBITDA for Dec 23 to be $11.58M, with a high of $11.88M and a low of $11.39M. This is -11.61% lower than Avanos Medical's previous annual EBITDA (Sep 23) of $13.10M.
Avanos Medical Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| Net Income | - | - | - | - | - | - | - | - | - | $-3.70M | $-68.10M | $-500.00K | $16.90M | $15.70M | - | $5.80M | $10.00M | $-35.10M | $37.90M | $-7.60M | $-47.20M | $19.30M | $-3.00M | $3.70M | $-6.10M | $-11.50M | $-8.00M | $-20.30M | $-2.20M | $4.20M |
| Avg Forecast | $25.46M | $22.69M | $19.75M | $16.20M | $22.07M | $16.36M | $13.27M | $7.02M | $16.98M | $12.96M | $13.77M | $6.38M | $22.69M | $-41.47M | $17.65M | $5.80M | $8.50M | $-37.70M | $41.20M | $-6.00M | $-34.33M | $15.49M | $-8.91M | $3.70M | $-5.72M | $-11.87M | $-8.00M | $-17.18M | $-1.37M | $2.67M |
| High Forecast | $25.50M | $22.72M | $19.78M | $16.23M | $22.10M | $16.38M | $13.29M | $8.42M | $17.89M | $13.89M | $13.79M | $7.66M | $22.72M | $-33.18M | $17.65M | $6.96M | $10.20M | $-30.16M | $49.43M | $-4.80M | $-27.46M | $18.59M | $-7.13M | $4.44M | $-4.58M | $-9.50M | $-6.40M | $-13.74M | $-1.09M | $3.20M |
| Low Forecast | $25.42M | $22.65M | $19.72M | $16.18M | $22.03M | $16.33M | $13.25M | $5.61M | $16.52M | $12.04M | $13.75M | $5.10M | $22.65M | $-49.76M | $17.65M | $4.64M | $6.80M | $-45.24M | $32.96M | $-7.20M | $-41.19M | $12.40M | $-10.69M | $2.96M | $-6.86M | $-14.25M | $-9.60M | $-20.61M | $-1.64M | $2.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.29% | -4.94% | -0.08% | 0.74% | -0.38% | - | 1.00% | 1.18% | 0.93% | 0.92% | 1.27% | 1.38% | 1.25% | 0.34% | 1.00% | 1.07% | 0.97% | 1.00% | 1.18% | 1.61% | 1.58% |
Avanos Medical's average Quarter net income forecast for Mar 23 is $6.38M, with a range of $5.10M to $7.66M. AVNS's average Quarter net income forecast represents a -62.25% decrease compared to the company's last Quarter net income of $16.90M (Dec 22).
Avanos Medical SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| SG&A | - | - | - | - | - | - | - | - | - | $78.70M | $93.00M | $92.70M | $82.60M | $82.10M | - | $90.10M | $75.20M | $75.00M | $76.70M | $73.40M | $82.20M | $82.40M | $76.90M | $91.10M | $103.60M | $94.40M | $94.70M | $106.40M | $87.90M | $86.30M |
| Avg Forecast | $88.31M | $85.07M | $83.11M | $80.36M | $84.14M | $80.87M | $78.77M | $109.02M | $78.67M | $78.28M | $85.99M | $99.11M | $100.30M | $88.61M | $96.13M | $90.10M | $63.92M | $80.56M | $83.37M | $57.95M | $59.78M | $66.15M | $68.27M | $91.10M | $97.13M | $97.45M | $94.70M | $90.03M | $54.65M | $54.77M |
| High Forecast | $88.40M | $85.15M | $83.19M | $80.44M | $84.23M | $81.04M | $78.85M | $130.83M | $80.70M | $78.47M | $86.07M | $118.93M | $100.40M | $106.33M | $96.13M | $108.12M | $76.70M | $96.67M | $100.04M | $69.54M | $71.74M | $79.39M | $69.09M | $109.32M | $116.55M | $116.93M | $113.64M | $108.04M | $65.58M | $65.72M |
| Low Forecast | $88.20M | $84.96M | $83.00M | $80.25M | $84.03M | $80.67M | $78.67M | $87.22M | $77.36M | $77.91M | $85.88M | $79.29M | $100.17M | $70.89M | $96.13M | $72.08M | $51.14M | $64.44M | $66.70M | $46.36M | $47.83M | $52.92M | $67.53M | $72.88M | $77.70M | $77.96M | $75.76M | $72.02M | $43.72M | $43.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 1.08% | 0.94% | 0.82% | 0.93% | - | 1.00% | 1.18% | 0.93% | 0.92% | 1.27% | 1.38% | 1.25% | 1.13% | 1.00% | 1.07% | 0.97% | 1.00% | 1.18% | 1.61% | 1.58% |
Avanos Medical's average Quarter SG&A projection for Dec 23 is $78.67M, based on 3 Wall Street analysts, with a range of $77.36M to $80.70M. The forecast indicates a -0.04% fall compared to AVNS last annual SG&A of $78.70M (Sep 23).
Avanos Medical EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.08 | $-1.46 | $-0.01 | $0.36 | $0.34 | - | $0.12 | $0.21 | $-0.73 | $0.79 | $-0.16 | $-0.99 | $0.40 | $-0.06 | $0.08 | $-0.13 | $-0.24 | $-0.17 | $-0.43 | $-0.05 | $0.09 |
| Avg Forecast | $0.55 | $0.49 | $0.43 | $0.35 | $0.48 | $0.35 | $0.29 | $0.21 | $0.37 | $0.28 | $0.30 | $0.28 | $0.49 | $0.35 | $0.38 | $0.26 | $0.40 | $0.29 | $0.23 | $0.18 | $0.22 | $0.10 | $-0.10 | $0.16 | $0.32 | $0.31 | $0.25 | $0.13 | $0.14 | $0.17 |
| High Forecast | $0.55 | $0.49 | $0.43 | $0.35 | $0.48 | $0.35 | $0.29 | $0.21 | $0.39 | $0.30 | $0.30 | $0.28 | $0.49 | $0.35 | $0.38 | $0.26 | $0.41 | $0.30 | $0.24 | $0.18 | $0.22 | $0.10 | $-0.10 | $0.16 | $0.32 | $0.32 | $0.26 | $0.13 | $0.17 | $0.20 |
| Low Forecast | $0.55 | $0.49 | $0.43 | $0.35 | $0.48 | $0.35 | $0.29 | $0.21 | $0.36 | $0.26 | $0.30 | $0.27 | $0.49 | $0.35 | $0.38 | $0.26 | $0.40 | $0.29 | $0.23 | $0.18 | $0.21 | $0.10 | $-0.10 | $0.16 | $0.31 | $0.31 | $0.25 | $0.13 | $0.11 | $0.13 |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.28% | -4.91% | -0.04% | 0.73% | 0.96% | - | 0.46% | 0.52% | -2.50% | 3.39% | -0.90% | -4.54% | 4.00% | 0.60% | 0.50% | -0.41% | -0.77% | -0.67% | -3.25% | -0.36% | 0.53% |
According to 1 Wall Street analysts, Avanos Medical's projected average Quarter EPS for Mar 23 is $0.28, with a low estimate of $0.27 and a high estimate of $0.28. This represents a -23.61% decrease compared to AVNS previous annual EPS of $0.36 (Dec 22).
Avanos Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NVRO | Nevro | $5.79 | $32.99 | 469.78% | Hold |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| ESTA | Establishment Labs | $44.20 | $78.00 | 76.47% | Buy |
| FNA | Paragon 28 | $7.39 | $11.50 | 55.62% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LIVN | LivaNova | $48.53 | $71.25 | 46.82% | Buy |
| CNMD | CONMED | $75.40 | $101.00 | 33.95% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| AORT | Artivion | $25.25 | $30.00 | 18.81% | Buy |
| AVNS | Avanos Medical | $24.00 | $27.00 | 12.50% | Hold |
| ITGR | Integer | $126.78 | $131.00 | 3.33% | Buy |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
| GKOS | Glaukos | $126.28 | $101.56 | -19.58% | Buy |
AVNS Forecast FAQ
Is Avanos Medical a good buy?
No, according to 2 Wall Street analysts, Avanos Medical (AVNS) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of AVNS's total ratings.
What is AVNS's price target?
Avanos Medical (AVNS) average price target is $27 with a range of $26 to $28, implying a 12.50% from its last price of $24. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Avanos Medical stock go up soon?
According to Wall Street analysts' prediction for AVNS stock, the company can go up by 12.50% (from the last price of $24 to the average price target of $27), up by 16.67% based on the highest stock price target, and up by 8.33% based on the lowest stock price target.
Can Avanos Medical stock reach $40?
AVNS's average twelve months analyst stock price target of $27 does not support the claim that Avanos Medical can reach $40 in the near future.
What are Avanos Medical's analysts' financial forecasts?
Avanos Medical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $691.07M (high $691.94M, low $689.96M), average EBITDA is $60.45M (high $65.41M, low $55.47M), average net income is $58.72M (high $60.19M, low $57.23M), average SG&A $352.81M (high $374.94M, low $330.59M), and average EPS is $1.33 (high $1.33, low $1.33). AVNS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $729.8M (high $730.51M, low $728.84M), average EBITDA is $49.58M (high $49.63M, low $49.52M), average net income is $84.11M (high $84.22M, low $83.97M), average SG&A $336.85M (high $337.18M, low $336.41M), and average EPS is $1.82 (high $1.82, low $1.81).
Did the AVNS's actual financial results beat the analysts' financial forecasts?
Based on Avanos Medical's last annual report (Dec 2022), the company's revenue was $820M, which missed the average analysts forecast of $828.84M by -1.07%. Apple's EBITDA was $122.9M, beating the average prediction of $65.04M by 88.95%. The company's net income was $50.5M, beating the average estimation of $4.67M by 982.44%. Apple's SG&A was $341.9M, missing the average forecast of $375.14M by -8.86%. Lastly, the company's EPS was $1.08, missing the average prediction of $1.48 by -27.25%. In terms of the last quarterly report (Sep 2023), Avanos Medical's revenue was $171.3M, beating the average analysts' forecast of $169.6M by 1.00%. The company's EBITDA was $13.1M, beating the average prediction of $11.52M by 13.69%. Avanos Medical's net income was $-3.7M, missing the average estimation of $12.96M by -128.54%. The company's SG&A was $78.7M, beating the average forecast of $78.28M by 0.53%. Lastly, the company's EPS was $-0.0791, missing the average prediction of $0.28 by -128.25%